Annoucement of the appointment of Eric Cazergue as Chief Financial Officer. Mr. Cazergue’s international career in finance roles within the healthcare industry will be a key asset supporting PathoQuest’s scale-up and global expansion efforts.
PathoQuest Appoints Colette Côté as Chief Portfolio Officer and General Manager of the Company’s U.S. Subsidiary
Annoucement of the appointment of Colette Côté, Ph.D. as Chief Portfolio Officer and General Manager of PathoQuest’s U.S. subsidiary located in Wayne, PA. Ms. Côté’s expertise and long history of innovating, developing, and applying tailored NGS-based assays to the biopharma biosafety testing space will further drive the expansion and growth of PathoQuest’s NGS-based services portfolio within the North American market.
PathoQuest announced that it has signed an agreement with the MIT to join the CAACB as an associate member. PathoQuest brings its 10-year experience in viral safety testing and quality control of biologics to contribute to research programs to help mitigate the risk of adventitious agent contamination in biopharmaceutical manufacturing. This collaboration is expected to translate into practical advances in this field and accelerate the adoption of NGS for the viral safety testing of biologics.
PathoQuest announces the appointment of Audrey Brussel, Ph.D. to the newly created position of Viral Safety Leader. Her addition to the company will strengthen PathoQuest’s in-house expertise in viral safety. Her insights and knowledge of the pharmaceutical industry from a customer’s perspective will help deliver a better service and support the growth of the company’s rapidly expanding quality control testing business for biologics.
PathoQuest receives PM’up Relance Industrie Île-de-France grant to expand biologic testing capabilities at Paris site
PathoQuest, has received support from the Île-de-France region (France) as part of the PM’up Relance Industrie program to accelerate the industrialization of the company’s high value-added service for quality control testing of biologics and to help sustain its fast-paced growth both in France and internationally.
PathoQuest has established a U.S. subsidiary, PathoQuest, Inc., and will construct a state-of-the-art next-generation sequencing (NGS)-based testing laboratory at Charles River’s site in Wayne, PA.